Humulin S (Soluble)

Humulin S (Soluble) is a prescription injectable solution that contains insulin human as the active ingredient, typically supplied at a concentration of 100 units per milliliter. It is a short‑acting insulin formulation approved for use in the European Union. The product is administered by subcutaneous, intramuscular, or intravenous injection to provide rapid glucose‑lowering effects in patients with diabetes. It is commonly used for mealtime insulin coverage alongside basal insulin.

Humulin S is indicated for the management of blood glucose in adults and children with diabetes.

- Type 1 diabetes mellitus, where endogenous insulin production is absent or minimal - Type 2 diabetes mellitus, particularly in patients who require additional short‑acting insulin to achieve glycemic targets - Mealtime (prandial) insulin therapy to cover carbohydrate intake, administered within 15 minutes before a meal - Correction of post‑prandial hyperglycemia when blood glucose exceeds target levels after meals - Use as part of a basal‑bolus insulin regimen, combined with a long‑acting insulin to provide both basal and prandial coverage

Adverse reactions to Humulin S can range from mild, frequently observed events to rare but serious conditions.

Common: - Hypoglycemia, which may manifest as sweating, tremor, hunger, dizziness, or confusion. - Redness, swelling, itching, or bruising at the injection site, usually mild and transient. - Lipohypertrophy (fat thickening) or lipoatrophy (fat loss) at areas where injections are repeatedly given. - Transient weight gain due to increased glucose utilization, fluid retention, or changes in appetite. - Nausea or mild abdominal discomfort, especially when doses are higher than usual. - Headache, which is usually mild and resolves without intervention.

Serious: - Severe hypoglycemia leading to loss of consciousness, seizures, or the need for external assistance. - Allergic reactions ranging from urticaria and angioedema to anaphylaxis, which require immediate medical attention. - Insulin‑induced edema or worsening of pre‑existing heart failure in susceptible individuals. - Serum‑sickness–like reaction characterized by fever, rash, arthralgia, and lymphadenopathy.

When prescribing or using Humulin S, clinicians and patients should consider several safety precautions to minimize risks and ensure appropriate therapy. - Assess renal and hepatic function, as impairment may alter insulin clearance. - Monitor blood glucose regularly to adjust dose and avoid hypoglycemia. - Educate patients on proper injection technique and site rotation to prevent lipodystrophy. - Use caution in pregnant or breastfeeding women; benefits must outweigh potential risks. - Review concomitant medications that may mask hypoglycemia symptoms. - Avoid use in patients with known hypersensitivity to human insulin or any excipients.

Humulin S may interact with other agents that affect glucose metabolism or insulin action, requiring dose adjustments or monitoring. Avoid: - Concurrent use of other rapid‑acting insulins or insulin analogues without proper dose reduction, which can cause severe hypoglycemia. - Beta‑blockers that mask hypoglycemia symptoms, making it harder to recognize low blood glucose. Use with caution: - Oral antidiabetic agents such as sulfonylureas, meglitinides, or SGLT2 inhibitors, which can increase the risk of hypoglycemia. - Corticosteroids, thiazide diuretics, or growth hormone therapy, which may raise blood glucose and necessitate higher insulin doses. - Alcohol consumption, especially in excess, as it can cause unpredictable glucose fluctuations.